QGC 001

Drug Profile

QGC 001

Alternative Names: Amino butane sulfonate disulfure; QGC-011; QGC001; RB 150

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator CNRS; INSERM; University Paris Descartes
  • Developer Quantum Genomics
  • Class Amines; Aminopeptidases; Antihypertensives; Disulfides; Metalloexopeptidases; Sulfonic acids
  • Mechanism of Action Glutamyl aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure; Hypertension

Most Recent Events

  • 29 Aug 2016 Investigation in Hypertension (Combination therapy) in France (Quantum Genomics pipeline, August 2016)
  • 03 May 2016 Phase-II clinical trials in Chronic heart failure in Norway (PO) (EudraCT2015-005607-92)
  • 26 Apr 2016 Quantum Genomics completes a phase II trial in Hypertension in France (PO) (NCT02322450)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top